Anlotinib, a tyrosine kinase inhibitor, has been shown to exert an anti-cancer effect in vitro on KRAS mutant lung cancer cells by inhibiting the MEK/ERK pathway [79]. Here, MAP2K7 is linked to lung carcinoma.